Pillar · Biotech Investing
Biotech Due Diligence Checklist: How to Evaluate a Drug Pipeline and Probability of Approval
Most biotech investors skip due diligence and pay the price. This step-by-step checklist walks you through everything yo...
Start here
Pillar · Clinical Readouts
How to Read Biotech Clinical Trial Data: Phase 1, 2, 3 Results Explained for Investors
Clinical trial data is the single most important factor in biotech investing, but most investors struggle to read it. Th...
Catalyst Analysis
Biotech Catalyst Trading: How Hedge Funds and Insiders Position Around FDA Decisions
The biggest moves in biotech happen around catalysts like PDUFA dates and data readouts. This guide reveals how top hedge funds like Baker Brothers and OrbiMed ...
Biotech Investing
How to Invest in Biotech Stocks: Beginner Guide to FDA Approvals, Clinical Trials and PDUFA Dates
Biotech investing is not like any other sector. A single FDA approval can send a stock up 100% overnight and a failed trial can wipe out 70% of a company's valu...
Biotech Investing
Respiratory Biotech Investing: Key Clinical Catalysts and Investor Outlook
Respiratory biotech stocks often surge on pivotal trial data or FDA approvals. Explore benchmarks, case studies, and investor strategies for this sector....
Biotech Investing
Cardiovascular Biotech Investing: High-Impact Catalysts and Market Insights
Cardiovascular biotech stocks often move on large outcomes trials or niche breakthroughs. Explore benchmarks, case studies, and strategies for investors....
Biotech Investing
Neurology Biotech Investing: Key FDA Catalysts & Investor Strategies
Explore how biotech catalysts in neurology create major opportunities for investors. Learn key benchmarks, case studies, and investing strategies....
Therapeutic Areas
Navigating Biotech Stock Catalysts: Insights from Clinical Phases and Therapeutic Areas
Discover the latest trends and investor insights into biotech stocks, exploring average stock price changes by therapeutic area and clinical phase, and historic...
FDA & PDUFA Calendar
Biotech Mid 2025 Catalysts: Nimacimab, Afrezza, VX-522, SGT-003 & More In Focus
Discover mid 2025 catalyst events in biotech: Skye Bioscience’s nimacimab, MannKind’s inhaled insulin Afrezza, Vertex’s VX-522 mRNA therapy, Solid’s SGT-003, Un...
Clinical Readouts
Phase 2 Biotech Catalysts to Watch This Week (June 12–16, 2025)
This week is packed with high-stakes biotech news as six companies release pivotal Phase 2 clinical trial data. From oncology to rare diseases and chronic condi...
FDA & PDUFA Calendar
Key FDA Decisions Approaching in April 2025 (PDUFA Date Calendar)
April 2025 is a key month for biotech and pharma, with the FDA set to make decisions on several significant drug applications. These decisions cover new formula...